Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry

  • Big corporations are investing in the cannabis industry
  • Major tobacco company provides financing for LXRP
  • LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors
  • Lexaria is a unique company doing business on its own terms

The cannabis industry is experiencing impressive growth thanks to both legal and social changes worldwide, and big corporations are stepping up to invest. In a new Audio Press Release (“APR”), PsychedelicNewsAudio praised Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (http://cnw.fm/Ap2N5) for building a large funding deal on its own terms. The APR, ‘Outside Investment, New Technology Support Growing Cannabis Industry’, highlighted Lexaria’s ability to create subsidiaries specializing in the use of DehydraTECH.

Through the deal, Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria, has received an initial investment in the amount of $1 million – with the option for funding to increase to up to $12 million – from one of the world’s largest tobacco companies; the capital has been earmarked for research and development (http://cnw.fm/G6v0R). Lexaria will maintain its independence, while the investing company receives only minority ownership of the subsidiary. This unique arrangement allows the tobacco company to buy into LXRP without Lexaria actually selling any of its parent company.

Lexaria is strategically positioned to benefit from new revenue streams based on this deal. The company will receive royalties on any nicotine products created with DehydraTECH and be able to showcase its unique technology to other industries.

In addition to Lexaria Nicotine, LXRP has three more wholly owned subsidiaries that are working in various industries to create new deals on Lexaria’s terms.

  • Lexaria CanPharm Corp. focuses on providing DehydraTECH to the global cannabis industry
  • Lexaria Hemp Corp. focuses on providing DehydraTECH to the hemp-based food and supplements industry
  • Lexaria Pharmaceutical Corp. focuses on licensing DehydraTECH to the pharmaceutical sectors

DehydraTECH is a drug-delivery platform patented for cannabidiol and all other non-psychoactive cannabinoids, as well as THC (tetrahydrocannabinol) and psychoactive cannabinoids. The technology is an enabling platform that works across multiple industries, thereby providing a large base of consumers with healthier forms of consumption than lighting up.

LXRP and DehydraTECH stand out among the competition. The company has a total of 10 patents issued with more than 50 patents pending worldwide. Few companies within the cannabis industry have attracted the attention of Fortune 500-type corporations, and even fewer are inking deals on their own terms. Lexaria Bioscience is one such stand-out.

For more information, visit the company’s website at www.LexariaBioscience.com

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

Do you have a questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050